jama glp 1 JAMA article on GLP-1 drugs: a closer look | Barry Sears posted on the topic

Ophthalmic Complications Observed After Use of GLP-1 Agonists

26.83

★★★★☆4.8 (126)

💬 Perspective: #GLP-1 receptor agonist therapy provides substantial weight loss but increases risk of muscle mass reduction; exercise, especially resistance training, shows efficacy in preventing weight regain and maintaining muscle mass. https://t.co

26.76

★★★★★4.9 (98)

On Monday, JAMA published a summary of the new @WHO recommendations on the use of #GLP1 in the treatment of obesity in adults. , In a webinar, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD,

26.70

★★★★★5.0 (157)

New JAMA Data Brief 📊 About 1 in 5 US adults with type 2 diabetes were already using the popular class of medications called glucagon-like peptide 1 (GLP-1) receptor agonists by 2022,

28.31

★★★★★4.7 (84)

Glucagon-like peptide-1 receptor agonists (#GLP1 RAs) may improve hidradenitis suppurativa outcomes by inducing weight loss and reducing inflammation. https://t.co/Rt1GQrkiWj

20.56

★★★★★4.9 (203)

From evidence to action: WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults

29.17

★★★★★5.0 (176)

Is That Ozempic Really Ozempic? What You Need to Know About GLP-1 Copycat Meds

20.56

★★★★★4.8 (132)